Myocyte enhancer factor 2 (MEF2) plays essential roles in transcriptional control of muscle development. However, signaling pathways acting downstream of MEF2 are largely unknown. Here, we performed a microarray analysis using Mef2c-null mouse embryos and identified a novel MEF2-regulated gene encoding a muscle-specific protein kinase, Srpk3, belonging to the serine arginine protein kinase (SRPK) family, which phosphorylates serine/arginine repeat-containing proteins. The Srpk3 gene is specifically expressed in the heart and skeletal muscle from embryogenesis to adulthood and is controlled by a muscle-specific enhancer directly regulated by MEF2. Srpk3-null mice display a new entity of type 2 fiber-specific myopathy with a marked increase in centrally placed nuclei; while transgenic mice overexpressing Srpk3 in skeletal muscle show severe myofiber degeneration and early lethality. We conclude that normal muscle growth and homeostasis require MEF2-dependent signaling by Srpk3.
Skeletal muscle differentiation is cooperatively controlled by two families of transcription factors, the myogenic basic helix-loop-helix (bHLH) proteins and the myocyte enhancer factor 2 (MEF2) family of MADS domain proteins (Black and Olson 1998; Bailey et al. 2001; Pownall et al. 2002; Buckingham et al. 2003; Parker et al. 2003) . Myogenic bHLH proteins, such as MyoD and myogenin, recognize a DNA sequence called an E box (CANNTG). Myogenic bHLH proteins associate and synergistically activate transcription with MEF2 factors, which bind to the A/T-rich DNA consensus [CTA-(A/ T) 4 -TA-G/A]. Additionally, myogenic bHLH proteins activate their own expression and the expression of MEF2, while MEF2 stimulates expression of myogenic bHLH protein genes and the Mef2c gene (Cserjesi and Olson 1991; Lassar et al. 1991; Edmondson et al. 1992; Cheng et al. 1993; Yee and Rigby 1993; Wang et al. 2001; Teboul et al. 2002; Dodou et al. 2003) . Such auto-and cross-regulatory interactions establish a mutually reinforcing circuit to achieve myogenesis.
The essential role of MEF2 in muscle development was first shown in Drosophila in which a loss-of-function mutation in the single MEF2 ortholog D-mef2 results in a complete block to differentiation of all muscle lineages: somatic, cardiac, and visceral (Bour et al. 1995; Lilly et al. 1995) . In mice, the existence of four Mef2 genes-Mef2a, Mef2b, Mef2c, and Mef2d-with overlapping expression patterns makes it more difficult to assess the roles of these factors individually (Black and Olson 1998) . Mice homozygous for a Mef2c-null allele show embryonic lethality around embryonic day 9.5 (E9.5) caused by improper development of the heart (Lin et al. 1997) . The mutant hearts do not undergo looping morphogenesis, the future right ventricle does not form, and a subset of cardiac muscle genes is not expressed. MEF2 has also been implicated in maintenance of the slow fiber phenotype of skeletal muscle, in the control of striated muscle energy metabolism, and in pathological remodeling of the adult heart in response to stress signaling (Black and Olson 1998; McKinsey et al. 2002) .
In principle, MEF2 may regulate muscle-specific target genes directly, or it may act indirectly by controlling the expression of subordinate transcription factors or signaling molecules that act as intermediaries to connect MEF2 to downstream targets that themselves are not dependent on MEF2-binding sites in their cis-regulatory regions. Indeed, vast arrays of direct and indirect targets of MEF2 in skeletal muscle cells in culture were recently described (Blais et al. 2005) .
In an effort to identify MEF2 target genes that serve as "downstream" effectors of MEF2 action during muscle development, we performed a microarray analysis using Mef2c-null embryos and identified a novel muscle-specific protein kinase Stk23/Srpk3, which is encoded by a direct MEF2 target gene. Srpk3-null mice display a new entity of centronuclear myopathy, while transgenic mice overexpressing Srpk3 in skeletal muscle show severe myofiber degeneration. These findings reveal an essential role for serine arginine protein kinase (SRPK)-mediated signaling in muscle growth and homeostasis downstream of MEF2 transcription factors.
Results

Srpk3: a novel muscle-specific protein kinase gene
In an attempt to identify novel MEF2-regulated genes, we compared the gene expression profiles of hearts from wild-type and Mef2c-null mouse embryos by an RNA microarray analysis. Because Mef2c-null embryos die around E9.5 (Lin et al. 1997) , we used hearts from wildtype and null embryos at E9.0 prior to overt cardiac demise. Among the genes that were dysregulated in the Mef2c mutants, we found the expression of Stk23 to be significantly decreased in the Mef2c-null hearts. The down-regulation of Stk23 expression in the Mef2c-null hearts was confirmed by RT-PCR (Fig. 1a) . Residual expression of Stk23 in the mutants may reflect the presence of other MEF2 factors that partially compensate for MEF2C.
Stk23 was described in an analysis of human chromosomal DNA methylation as a potential protein-kinaseencoding gene (Grunau et al. 2000) , but its expression profile and function have not been described. Structural comparison with various protein kinases clearly indicated that Stk23 possesses a bipartite kinase domain with high sequence similarity to the SRPK family kinases, Srpk1 and Srpk2 (Fig. 1b,c ; Gui et al. 1994; Bedford et al. 1997; Kuroyanagi et al. 1998; Wang et al. 1998) . As expected, Stk23 efficiently phosphorylated known SRPK substrates, the splicing factor SF2/ASF, and Lamin B Receptor in in vitro kinase assays ( Fig. 1d ; Nikolakaki et al. 1997; Koizumi et al. 1999; Yeakley et al. 1999; Takano et al. 2002) . Therefore, we propose a functionally descriptive nomenclature, Srpk3, for Stk23.
In situ hybridization with mouse embryos showed Srpk3 to be specifically expressed in the developing heart, somites, and skeletal muscles, in contrast to broad expression of Srpk1 and Srpk2 (Fig. 2a) . Expression in the heart was first detected in the heart tube, immediately following expression of MEF2C, and expression in the somite myotomes was observed by E9.5. Within the embryonic heart, Srpk3 is expressed throughout the atrial and ventricular chambers (Fig. 2a) . Srpk3 is highly expressed in the heart and skeletal muscle in adult mice (Fig. 2b) . Muscle-specific expression was also observed in human fetal and adult tissues ( Supplementary Fig. 1 ).
Regulation of the Srpk3 promoter by MEF2
To examine if Srpk3 is transcriptionally regulated by MEF2, we performed reporter analyses in vitro and in vivo. MEF2C and MyoD significantly activated the expression of a luciferase reporter controlled by a 2.9-kb DNA fragment encompassing the 5Ј Srpk3 promoter region, and serial deletion analysis revealed that a 0.4-kb fragment was sufficient for the activation by MEF2C and MyoD (Fig. 3a) . Indeed, the 0.4-kb fragment contains a MEF2-binding site and two E boxes (Fig. 3b) . Although there are also two GATA sites in the 0.4-kb fragment, GATA proteins did not enhance Srpk3 promoter activity in luciferase assays (data not shown). An oligonucleotide probe, containing the MEF2 site and E boxes in the Srpk3 promoter, was bound by MEF2C as well as by myogenin and its ubiquitous bHLH dimerization partner, E12 (Fig.  3c) . Mutation of the MEF2 site in the context of the 2.9-or 0.4-kb fragment significantly decreased the response to MEF2C and MyoD in luciferase assays (Fig. 3d) , suggesting that MEF2 is an obligate activator of the Srpk3 promoter.
Transcriptional control of Srpk3 during myogenic differentiation in vitro
We next examined the expression of Srpk3 mRNA during differentiation of C2C12 myoblasts, which are triggered to differentiate and form myotubes upon transfer to medium with low serum . Srpk3 mRNA was not expressed in C2C12 myoblasts but was markedly induced together with embryonic and perinatal myosin genes, Myh3 and Myh8, during myogenesis (Fig. 3e) .
Consistently, expression of a luciferase reporter controlled by the Srpk3 promoter was markedly enhanced during differentiation of C2C12 cells (Fig. 3f) . Mutation of the MEF2 site almost abolished the promoter activity, suggesting that Srpk3 expression is activated upon myogenic differentiation directly by MEF2 proteins.
Transcriptional control of Srpk3 in vivo
We further examined the transcriptional regulation of Srpk3 expression in transgenic mice. The 2.9-kb and 0.4-kb Srpk3 regulatory regions fused to the HSP68 basal promoter (Fig. 4a ) directed the expression of a LacZ reporter in the embryonic heart and somites (Fig. 4b,c) , recapitulating the muscle-specific expression pattern of the endogenous gene. The 0.4-kb fragment was also sufficient to direct muscle-specific expression without the HSP68 minimal promoter (data not shown). Analyses of embryo sections confirmed that LacZ expression was observed throughout cardiac muscle walls, including the outflow tract, and in the somite myotomes (data not shown).
Consistent with the luciferase reporter analyses, the mutation of the MEF2-binding site in the context of the 0.4-kb fragment completely abolished LacZ expression in the heart and somites. Ten out of 16 transgenic embryos harboring the transgene with the mutant MEF2 site showed no LacZ staining (Fig. 4d) , and the remaining showed weak ectopic expression that was not specific to the heart and somites. In contrast, mutation of the two E boxes did not result in a significant decrease of LacZ expression in the heart and somites (Fig. 4e ). We conclude that Srpk3 is a direct transcriptional target of MEF2 proteins in vivo.
Muscle defects in Srpk3 transgenic mice
SRPKs are known to regulate mRNA splicing and the assembly of nuclear lamina proteins, by phosphorylating SR splicing factors and Lamin B Receptor (Gui et al. 1994; Bedford et al. 1997; Nikolakaki et al. 1997; Kuroyanagi et al. 1998; Wang et al. 1998; Koizumi et al. 1999; Yeakley et al. 1999; Takano et al. 2002) . RNAi experiments showed that SRPK is essential for germline development in Caenorhabditis elegans (Kuroyanagi et al. 2000) , but in vivo functions of the SRPK family have not been examined in mammals.
To analyze the effects of excessive SRPK activity in striated muscles, we generated transgenic mice overex- pressing Srpk3 in skeletal muscle, using the muscle creatine kinase (MCK) gene promoter and enhancer (Sternberg et al. 1988) . Multiple F0 transgenic mice died prematurely with severe muscle wasting and growth retardation. Two F0 mice survived to sexual maturity and were fertile, but the F1 transgenic mice derived from these founders died at 2-8 wk of age, which prevented us from establishing transgenic mouse lines. However, those transgenic mice shared muscle defects with myofiber disarray and degeneration (Fig. 5a-c) . These mice also showed myocyte regeneration characterized by an increase in centrally placed nuclei (Fig. 5c ) and activation of embryonic gene markers (Fig. 5d ). Although these characteristics are similar to those of muscular dystrophy, Evans Blue dye injection did not show abnormalities of sarcolemmal integrity (data not shown), and the expression of dystrophin and related sarcolemmal proteins was intact ( Supplementary Fig. 2 ), suggesting that excess SRPK activity causes muscle degeneration by a different mechanism.
Centronuclear myopathy in Srpk3-null mice
To further elucidate the significance of Srpk3 in vivo, we generated Srpk3-null mice (Fig. 6a-c) . The mutation we introduced into the gene deleted parts of exons 1 and 5 and all of exons 2, 3, and 4, which encode the N-terminal portion of Kinase Domain 1 (Fig. 6a) . Northern analysis showed the complete absence of Srpk3 transcripts in the heart and skeletal muscle of mutant mice (Fig. 6c) .
Since the Srpk3 gene is located on the X chromosome, wild-type and hemizygously null male mice were examined in this study. Srpk3-null mice were viable to adulthood, but displayed apparent defects in skeletal muscle growth. The mass of various skeletal muscle groups was significantly smaller than that of wild-type littermates at 1 mo ( Fig. 6d ) and 3 mo of age (data not shown). Histological analysis revealed a marked increase in centrally placed nuclei and a disorganized intermyofibrillar network, occasionally with ring-fiber-like structure or spheroid bodies ( Fig. 6e,f; data not shown).
The pathological characteristics of Srpk3-null muscle were different from those of MCK-Srpk3 transgenic mice. Although an increase in centrally placed nuclei is frequently indicative of muscle regeneration in response to disease or injury (Garry et al. 2000; Carpenter and Karpati 2001; Emery 2002) , Srpk3-null mice did not show up-regulation of embryonic/perinatal muscle markers, which is typically seen during muscle regeneration (Fig. 6g ). There were no signs of inflammation, neutrophil infiltration, or fibrosis in Srpk3-null mice (Fig. 6e) , nor was there an increase in apoptotic cell death detectable by TUNEL staining (Fig. 6f) . The serum creatine kinase activity indicative of sarcolemmal leakage also did not significantly increase in Srpk3-null mice (wild type, 409 ± 192; null, 486 ± 291; IU/L, n = 10), and Evans Blue dye injection did not show abnormalities of sarcolemmal integrity (Fig. 6f) .
The pathological characteristics of the skeletal muscle in Srpk3-null mice, especially an increase of centronucleated myofibers without apparent myocyte death, are reminiscent of human centronuclear myopathy (Carpenter and Karpati 2001; Jeannet et al. 2004 ). However, centrally placed nuclei were observed only in type 2 fi- bers, but not in type 1 fibers, in Srpk3-null mice (Fig. 6f) , in contrast to type 1 fiber specific abnormalities associated with human centronuclear myopathy (Laporte et al. 1996; Carpenter and Karpati 2001; Jeannet et al. 2004 ). These results suggested that Srpk3-null mice displayed a new entity of centronuclear myopathy.
Alteration of muscle gene expression in Srpk3-null mice
To further characterize muscle abnormalities of Srpk3-null mice, we examined the expression of various muscle genes in type 2 fiber-enriched tibialis anterior muscles. A subset of type 1/slow fiber-enriched genes showed increased expression in Srpk3-null mice; however, the lack of activation of two representative slowtwitch fiber markers (Serrano et al. 2001; McCullagh et al. 2004) , Slc2a4/Glut4 and Myoglobin (Mb), suggests that the altered gene expression patterns are not a simple reflection of fiber type switching (Fig. 7a) . Consistently, expression of type 2/fast fiber-enriched genes (Fig. 7a) as well as the proportions of type 1 and 2 fibers were not altered in Srpk3-null mice (wild type: type 1, 14.6%; type 2, 85.4%, n = 700; Srpk3 null: type 1, 17.9%; type 2, 82.1%, n = 800).
Although there was a significant decrease of muscle mass in Srpk3-null mice, most atrophy-related genes (McKinnell and Rudnicki 2004) did not show alteration of expression in Srpk3-null mice. However, we observed a significant increase in expression of the cartilage intermediate layer protein (Cilp) gene (Fig. 7b) , which encodes a secreted inhibitor of transforming growth factors and insulin-like growth factors (Lorenzo et al. 1998; Johnson et al. 2003; Seki et al. 2005) . Given the importance of growth factor signaling in muscle diseases (McKinnell and Rudnicki 2004) , up-regulation of Cilp expression may contribute, at least in part, to myopathy and muscle growth defects in Srpk3-null mice.
Calcium homeostasis plays critical roles in the regulation of skeletal muscle growth and contractility, and abnormalities in calcium handling have been implicated in various muscle diseases (MacLennan et al. 2003) . Interestingly, mRNA expression of Sarcolipin (Sln) markedly increased in Srpk3-null mice (Fig. 7) . Sln shares structural and functional similarity with Phospholamban, and they physically associate with and inhibit sarco(endo)plasmic reticulum calcium ATPase (Tupling et al. 2002; MacLennan et al. 2003) . Forced expression of Sln in skeletal muscle represses sarcoplasmic reticulum calcium uptake and impairs contractile function (Tupling et al. 2002) . Despite its important function, the expression patterns of Sln in muscle diseases have not been previously studied. We also observed that Sln expression increased in dystrophic Mdx mice as well as in cardiotoxin muscle injury models (Garry et al. 2000; Carpenter and Karpati 2001; Emery 2002 ; data not shown). How Sln expression is regulated in those conditions is unknown, but up-regulation of Sln expression may be a common characteristic of muscle diseases.
Discussion
MEF2 is a key regulator of cardiac and skeletal muscle development as well as remodeling of adult muscles in response to physiologic and pathologic signals (Black and Olson 1998; McKinsey et al. 2002) . While MEF2 has been shown to regulate a wide range of muscle structural genes, few other target genes that might mediate its actions in muscle have been identified (Kuisk et al. 1996; Anderson et al. 2004; Phan et al. 2005) . The results of the present study identify Srpk3 as a novel muscle-specific protein kinase, which is directly regulated by MEF2 and is essential for normal growth and homeostasis of skeletal muscle.
Abnormalities in skeletal muscle resulting from dysregulation of Srpk3
Striated muscles are highly sensitive to the level of Srpk3 expression. Overexpression of Srpk3 in skeletal muscle causes severe myofiber abnormalities, while overexpression in the heart results in dilated cardiomyopathy characterized by chamber dilatation, reduced contractility, and disease marker expression (M. Arnold, M. Nakagawa, H. Hamada, O. Nakagawa, J.A. Richardson, and E.N. Olson, unpubl.) . Conversely, targeted deletion of the Srpk3 gene results in a unique form of skeletal myopathy with a marked increase in centrally placed nuclei. The histological characteristics of these mice share similarity with those in human centronuclear myopathy, a congenital myopathy characterized by the presence of numerous centronuclear myofibers (Laporte et al. 1996; Carpenter and Karpati 2001; Jeannet et al. 2004) . Central placement of myonuclei occurs in various pathological conditions and commonly accompanies the regeneration process following myofiber degeneration and death (Garry et al. 2000; Carpenter and Karpati 2001; Emery 2002) . In response to muscle injury, quiescent muscle progenitor cells, called satellite cells, are acti- vated and differentiate into new myofibers with centrally placed nuclei as are also seen in newly formed muscle fibers during embryonic development. However, in contrast to muscular dystrophy models, Srpk3-null mice did not show histological signs of myocyte death or reactivation of early developmental markers, which typically accompanies regeneration. Instead, the skeletal muscle of Srpk3-null mice may retain partially immature characteristics, although myofiber differentiation in these mice apparently progresses beyond the stages with embryonic and perinatal myosin expression. The conclusion that centronuclear myopathy in Srpk3 mutant mice reflects a developmental abnormality is also supported by the absence of signs of muscle degeneration and regeneration, such as muscle cell death, myofiber disarray, or neutrophil infiltration, at early ages (data not shown).
The only gene shown to be involved in human centronuclear myopathy is myotubularin 1 (MTM1), which encodes a ubiquitously expressed dual-specificity phosphatase (Laporte et al. 1996 (Laporte et al. , 2003 Buj-Bello et al. 2002) . Mutations of MTM1 cause an X-linked form of centronuclear myopathy, characterized by an immature myotube-like appearance of skeletal muscle (Carpenter and Karpati 2001; Laporte et al. 2003) . Null mutation of the Mtm1 gene also causes centronuclear myopathy in mice (Buj-Bello et al. 2002) . Muscle growth defects in Mtm1-null mice are more severe than those of Srpk3-null mice, and centrally placed nuclei are observed predominantly in type 1 fibers. However, these two models share similar features, such as the proportions of centronuclear myofibers and the lack of inflammation, apoptosis, and sarcolemmal disruption. The Myotubularin substrates that are related to skeletal muscle abnormalities remain unidentified. Perhaps there is cross-talk of signaling pathways downstream of Srpk3 and Myotubularin. The phenotype of Srpk3 null mice also raises the question whether mutations in the SRPK3 gene might be responsible for human myopathies that have not yet been ascribed to a specific gene.
Cellular functions of SRPK in skeletal muscle
The SRPK family of protein kinases is highly conserved among species; Sky1p and Dsk1 in yeast, SPK-1 in C. elegans, SRPK in Drosophila, and Srpk1 and Srpk2 in mice and humans (Gui et al. 1994; Bedford et al. 1997; Kuroyanagi et al. 1998 Kuroyanagi et al. , 2000 Tang et al. 1998; Wang et al. 1998; Siebel et al. 1999) . SRPKs phosphorylate serine/ arginine (SR)-rich domain proteins and modulate their protein-protein interactions and intracellular localization. For example, unphosphorylated SR splicing factors associate with SRPK in the cytoplasm and, once phosphorylated, dissociate from SRPK and are translocated to the nucleus (Koizumi et al. 1999; Yeakley et al. 1999) .
In this regard, it is interesting to note that abnormal mRNA splicing has been implicated in a variety of muscle diseases (Maniatis and Tasic 2002) , and cardiacspecific deletion of the SR splicing factor genes, Sfrs1 and Sfrs2, causes dilated cardiomyopathy in mice (Ding et al. 2004; Xu et al. 2005) . Additionally, splicing defects of the tyrosine phosphatase-like gene, Ptpla, lead to centronuclear myopathy in dogs (Pele et al. 2005) . SRPKs also phosphorylate Lamin B Receptor, an integral protein in the inner nuclear membrane or nuclear lamina (Nikolakaki et al. 1997; Ye et al. 1997; Takano et al. 2002) . Mutations of the genes encoding the nuclear lamina proteins, Emerin or Lamin A/C, cause Emery-Dreifuss type muscular dystrophy (Wilson 2000) . Thus, it is tempting to speculate that defects of mRNA splicing or nuclear lamina assembly contribute to the muscle abnormalities in Srpk3-null and Srpk3 transgenic mice.
It should also be pointed out that proteins without typical SR-rich domains have recently been shown to serve as SRPK substrates (Daub et al. 2002) . Although Srpk3 expression is equivalent in type 1-and type 2-enriched muscles (data not shown), there is apparent fiber type specificity of the muscle pathology in Srpk3-null mice, suggesting the involvement of Srpk3 in muscle functions that are important in type 2 fibers, such as glycolytic metabolism. The abnormal muscle gene expression profiles of Srpk3-null mice suggest roles of Srpk3 in growth factor signaling and calcium homeostasis. Identification of muscle-enriched SRPK substrates will provide further insights into functions of Srpk3 in muscle development and disease.
MEF2 as a nexus of kinase signaling pathways
A variety of kinase signaling pathways have been shown to augment MEF2 activity (McKinsey et al. 2002) . Signaling by p38 MAP kinase, for example, results in phosphorylation of the transcription activation domain of MEF2 and consequent enhancement of transcriptional activity , while the MAP kinase ERK5 interacts directly with MEF2 and serves as a transcriptional coactivator (Kato et al. 1997; Yang et al. 1998; Kasler et al. 2000) . In addition, signaling by calcium/ calmodulin-dependent kinase and protein kinases C and D induces MEF2 activity by releasing the repressive influence imposed by class II histone deacetylases Vega et al. 2004) . The results of this study, which show that MEF2 is an obligate activator of Srpk3 expression, point to MEF2 as a nexus between upstream and downstream kinase signaling pathways that control muscle development and function.
Materials and methods
Mef2c-null embryos, microarray analysis, and cloning of Srpk3 cDNA
Since Mef2c-null embryos die around E9.5 (Lin et al. 1997) , the hearts from the wild-type and Mef2c-null embryos were collected prior to overt cardiac demise at E9.0. Microarray analysis was performed using 1 µg of total RNA as previously described (Belbin et al. 2002) . The data were queried for difference of signal intensity between two samples, reproducibility in dye swap arrays, and signal intensity compared with local background. A clone that showed decreased signals in the hybridization with Mef2c-null embryo-derived RNA probes was identical to a part of mouse Stk23/Srpk3 cDNA sequence (NM_019684). Fulllength Srpk3 cDNA fragments were isolated by screening of an embryonic heart cDNA library (Stratagene), using partial cDNA fragments obtained from the EST resources as a probe. Fulllength cDNA fragments of human SRPK3 were also obtained from the EST resources.
Cell culture
C2C12 myoblasts were maintained in the growth medium containing 10% fetal calf serum, and the plasmid transfection was performed using Lipofectamine (Invitrogen) according to the manufacturer's instructions. Myogenic differentiation of C2C12 cells was triggered by the transfer to the differentiation medium containing 2% horse serum . For the luciferase assays during the course of differentiation, C2C12 cells were transfected with the plasmids in growth medium, and myogenic differentiation was stimulated 2 d after the transfection.
Srpk3 transgenic mice
Transgenic mice overexpressing Flag-tagged Srpk3 were generated using the MCK promoter/enhancer (Sternberg et al. 1988) . Genotyping was performed by Southern blot analysis, and the skeletal muscle-specific expression of Flag-Srpk3 was confirmed by Western blot analysis.
Srpk3-null mice
A BAC clone containing the Srpk3 gene was obtained by screening of a 129s6/SvEvTAC mouse genomic BAC library (BACPAC Resources). The targeting vector was linearized and electroporated into mouse embryonic stem cells of 129Sv origin. Correctly targeted embryonic stem cell clones, as identified by Southern blotting using both 5Ј and 3Ј probes, were injected into blastocysts isolated from C57BL/J mice. Chimeras obtained from these blastocyst injections were bred to obtain heterozygous mice that carry the targeted Srpk3 locus in their germline. Genotyping was performed by Southern blot analysis and PCR (primers: 5W, 5Ј-AGGTCTTCCTTGGCTAGTCCTACACTGT GG-3Ј; 3W, 5Ј-TAGTCCTTAGGGTCTTCCTGTTCCTCAT C-3Ј; and 3L, 5Ј-CCATGGTGGATCCTGAGACTGGGGAATT C-3Ј). Srpk3-null mice in the pure 129s6/SvEvTAC background and the mixed 129s6/SvEvTAC-C57BL6/J background showed identical skeletal muscle pathology.
In situ hybridization
Whole-mount and radioactive section in situ hybridization was performed as described (Nakagawa et al. 1999 ), using Srpk1/-2/-3 RNA probes. For each gene, identical results were obtained using two probes that were prepared using different cDNA fragments.
Northern blot analysis
Northern blot analysis of the SRPK family genes was performed on mouse and human poly(A) + RNA blots (Clontech), as described (Nakagawa et al. 1999) . Northern blot analysis of muscle genes was performed using total RNA of the tibialis anterior muscle of Srpk3-null and wild-type mice. cDNA fragments for probe preparation were prepared by RT-PCR or were obtained from the EST resources. Detailed information of the cDNA probes is available upon request.
RT-PCR
RT-PCR was performed using Superscript II reverse transcriptase (Invitrogen) and Advantage2 DNA polymerase (Clontech). Primer sequences are available upon request.
Luciferase and LacZ reporter analyses
Three different Srpk3 genomic DNA fragments, which had the identical 3Ј-ends at the translational start site, were ligated into a luciferase reporter plasmid, pGL3 basic (Promega). The genomic DNA fragments were also ligated into a promoter-less LacZ reporter plasmid or a LacZ reporter plasmid containing the HSP68 minimal promoter sequence (Wang et al. 2001) . Mutations were introduced by PCR into a MEF2-binding site (wildtype, 5Ј-GGCTATTTATAAAG-3Ј; mutant, 5Ј-GGCTAGGGC TAAAG-3Ј) and E boxes (wild-type, 5Ј-CAGCTG-3Ј; mutant, 5Ј-ACGCGT-3Ј) in the Srpk3 regulatory region of the reporter plasmids. Luciferase assays were performed in C2C12 cells, and LacZ reporter assays of F0 transgenic mouse embryos were per-formed as previously described (Nakagawa et al. 2000; Wang et al. 2001) .
Electrophoretic mobility shift assay
The cell lysates containing MEF2C, myogenin, and/or E12 were prepared from COS1 cells transfected with combinations of expression plasmids. In vitro binding analysis was performed as previously described (Wang et al. 2001) , using oligonucleotide fragments that contained a MEF2-binding site and E boxes (underlined) in the Srpk3 promoter (5Ј-CTTGCCCACAGCTGAG CAGCTGGGAGGCTATTTATAAAGGCGAG-3Ј). The oligonucleotide fragments with a mutated MEF2-binding site (5Ј-GGCTAGGGCTAAAG-3Ј) and those with mutated E boxes (5Ј-ACGCGT-3Ј) did not show binding by MEF2C and the myogenin/E12 complex, respectively (data not shown).
In vitro phosphorylation assays
Myc-tagged proteins of full-length SF2/ASF (Koizumi et al. 1999) and the N terminus of Lamin B Receptor (Ye et al. 1997) were prepared by in vitro transcription and translation using TNT reticulocyte lysate system (Promega). Myc-Srpk3 and the control sample prepared using the empty plasmid vector were also prepared by the TNT reaction. Proteins were immunoprecipitated using rabbit polyclonal anti-Myc antibody (Santa Cruz), and in vitro kinase reaction was performed with [␥-32 P]ATP at 30°C.
Histological analysis of skeletal muscle
Histological staining of skeletal muscles, myofiber typing by the ATPase staining, TUNEL staining, and the Evans Blue dye injection were performed as previously described (Woods and Ellis 1996; Wu et al. 2000; Lu et al. 2002; Kanagawa et al. 2004 ).
